Head-To-Head Analysis: Palladyne AI (NASDAQ:PDYN) vs. Mainz Biomed (NASDAQ:MYNZ)

Mainz Biomed (NASDAQ:MYNZ) and Palladyne AI (NASDAQ:PDYN) are both small-cap industrials companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Profitability

This table compares Mainz Biomed and Palladyne AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Palladyne AI	-254.75%	-53.29%	-40.05%

Earnings & Valuation

This table compares Mainz Biomed and Palladyne AI”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659,935.00	21.97	-$21.65 million	($65.60)	-0.02
Palladyne AI	$5.25 million	53.38	$10.04 million	($0.68)	-8.35

Palladyne AI has higher revenue and earnings than Mainz Biomed. Palladyne AI is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

26.0% of Palladyne AI shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 13.4% of Palladyne AI shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Palladyne AI has a beta of 3.67, indicating that its stock price is 267% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Mainz Biomed and Palladyne AI, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1	1	0	0	1.50
Palladyne AI	1	2	3	0	2.33

Palladyne AI has a consensus target price of $11.00, indicating a potential upside of 93.66%. Given Palladyne AI’s stronger consensus rating and higher probable upside, analysts clearly believe Palladyne AI is more favorable than Mainz Biomed.

Summary

Palladyne AI beats Mainz Biomed on 9 of the 14 factors compared between the two stocks.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

About Palladyne AI

Palladyne AI Corp., a software company, focuses on delivering software that enhances the utility and functionality of third-party stationary and mobile robotic systems in the United States. Its Artificial Intelligence (AI)/ Machine Learning (ML) software platform enables robots to observe, learn, reason, and act in structured and unstructured environments. The company's software platform enables robotic systems to perceive their environment and quickly adapt to changing circumstances by generalizing from their experience using dynamic real-time operations without extensive programming and with minimal robot training. It serves customers from various industries, such as industrial manufacturing, warehousing and logistics, defense, infrastructure maintenance and repair, energy, aerospace and aviation, and others. The company was formerly known as Sarcos Technology and Robotics Corporation and changed its name to Palladyne AI Corp. in March 2024. Palladyne AI Corp. was founded in 2017 and is headquartered in Salt Lake City, Utah.